Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,444 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pharmacodynamics Clear all

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Treprostinil sodium for inhalation; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more

Conditions: Leukemia, Lymphocytic
Interventions: enzastaurin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Duarte, California • Chicago, Illinois • New York, New York + 1 more

Conditions: Healthy
Interventions: AZD1722, Omeprazole; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Advanced Solid Tumor
Interventions: SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Healthy Participants
Interventions: BOS161721, Placebo; Drug
Lead sponsor: Boston Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Acalabrutinib (Arm A), Acalabrutinib (Arm B); Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Acute Lymphoblastic, Leukemia
Interventions: Not listed
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Year to 24 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Small Cell Lung Carcinoma
Interventions: BMS-833923, Carboplatin, Etoposide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Chronic Hepatitis C
Interventions: ANZ-521, Placebo; Drug
Lead sponsor: Anza Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Anaheim, California • San Antonio, Texas

Conditions: Uveal Melanoma
Interventions: PAC-1, Entrectinib; Drug
Lead sponsor: Arkadiusz Z. Dudek, MD; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Obese
Interventions: NGM313, Pioglitazone; Biological · Drug
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Metahdone-maintenance Subjects
Interventions: MOA-728; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: CAH - Congenital Adrenal Hyperplasia
Interventions: Crinecerfont; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 14 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: San Diego, California • Aurora, Colorado • Ann Arbor, Michigan + 3 more

Conditions: Fibrosis
Interventions: BMS-986263, Placebo, Diphenhydramine, Famotidine; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hypercholesterolemia
Interventions: CIVI 007; Drug
Lead sponsor: Civi Biopharma, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Jacksonville, Florida • Port Orange, Florida • Indianapolis, Indiana + 4 more

Conditions: Solid Tumor, Adult, Solid Tumor Cancer
Interventions: DF6215, pembrolizumab, KEYTRUDA®; Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Diego, California + 5 more

Conditions: Healthy
Interventions: PF-06412562; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetic Kidney Disease (DKD)
Interventions: ALN-ANG3, Evinacumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 59
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more

Conditions: MItochondrial Myopathies
Interventions: Omaveloxolone capsules, 2.5 mg, omaveloxolone capsules, 5 mg, omaveloxolone capsules, 10 mg, Placebo capsules, omaveloxolone capsules, 20 mg, omaveloxolone capsules, 40 mg, omaveloxolone capsules, 80 mg, omaveloxolone capsules, 160 mg; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Los Angeles, California • Boston, Massachusetts • Akron, Ohio + 4 more

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 6 more

Conditions: Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
Interventions: PQ203; Drug
Lead sponsor: ProteinQure Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Houston, Texas • San Antonio, Texas • West Valley City, Utah

Conditions: Acute Pancreatitis
Interventions: CM4620-IE; Drug
Lead sponsor: CalciMedica, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Advanced Solid Tumor
Interventions: Mirdametinib 2mg, BGB-3245 5mg, Mirdametinib 3mg, Mirdametinib 4mg, BGB-3245 10mg, BGB-3245 20mg; Drug
Lead sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: La Jolla, California • New Haven, Connecticut • Boston, Massachusetts + 3 more

Conditions: Acute Kidney Injury
Interventions: CXA-10, CXA-10 placebo; Drug · Other
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Search by objective public record fields.

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

A Study of Enzastaurin in Patients With Leukemia

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

Study of SRF617 in Patients With Advanced Solid Tumors

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Vincristine PK and PD in the AYA Population Compared to Younger Children

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Study of NGM313 in Obese Participants

Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

Study of DF6215 in Patients With Advanced Solid Tumors

A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis

Mirdametinib + BGB-3245 in Advanced Solid Tumors

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects